Italia markets close in 2 hours 58 minutes
FTSE MIB
35.380,47 -29,66 (-0,08%) Dow Jones
39.869,38 -38,62 (-0,10%) Nasdaq
16.698,32 -44,07 (-0,26%) Nikkei 225
38.787,38 -132,88 (-0,34%) Petrolio
79,25 +0,02 (+0,03%) Bitcoin EUR
61.155,37 -84,57 (-0,14%)
NBIX May 2024 100.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 11:28AM EDT. Mercato aperto.
| Chiusura precedente | 1,4000 |
| Aperto | 1,4000 |
| Denaro | 0,7500 |
| Lettera | 1,1000 |
| Prezzo d'esercizio | 100,00 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 1,4000 - 1,4000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 60 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.